TickerGuard
Buy Day today: Neutral (59) Mixed market breadth · major macro event coming up
SY

So-Young International Inc

Healthcare · Health Information Services · listed since 2019

2.20$ -2.2% vs. previous close Closing price · As of: Aug 13, 2026
🔔 Watch stock
Add to watchlist

Stock Watch

Stock Watch will tell you what changes at So-Young International Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Price history

Chart

Interactive price chart (TradingView).

52-week range: 1.30 $ to 5.10 $ · Last price: 2.20 $ (As of: August 13, 2026)

Key figures

Key figures at a glance

Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.

Basics

Market Cap ?The value of the entire company on the market: share price times total shares outstanding. 0.2$B
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. –
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. –
Beta ?Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market. –

Performance

Perf. 1M ?Price performance over the last month. 29.20%
Perf. 3M ?Price performance over the last 3 months. -27.30%
Perf. 6M ?Price performance over the last 6 months. -35.20%
YTD Performance (%) ?Price performance since the start of the year (Year to Date). -13.67%
52-Week-High Distance ?How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high. -56.7%
Perf. 1Y ?Price performance over the last 12 months. -56.86%
Perf. 3Y ?Price performance over the last 3 years. 72.79%
Perf. 5Y ?Price performance over the last 5 years. -62.41%
Perf. Since Inception ?Price performance since the first available trading day (05/02/2019) — with a complete history, that is since the IPO. -86.80%

Technical Indicators

MA 38 Days ?Moving average of the last 38 trading days: the smoothed price path. A price above it signals short-term strength. 1.80$
MA 50 Days ?Moving average of the last 50 trading days — the most widely watched medium-term trend line. 1.80$
MA 200 Days ?Moving average of the last 200 trading days — the dividing line between a long-term uptrend and downtrend. 2.70$
RSI (14) ?Relative Strength Index over 14 days, scale 0 to 100: above 70 counts as overbought, below 30 as oversold. A hint on timing, not a verdict on the company. 63.5
Volatility 30 Days ?Price swings over the last 30 trading days, annualized. The higher the value, the more the price fluctuates. 70.7%
Volatility 250 Days ?Price swings over the last 250 trading days (roughly one market year), annualized. 83.2%

Calculated from the price history · as of 08/14/2026

Valuation

P/E ?Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E. –
Forward P/E ?P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future. –
PEG ?P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey. –
P/B ?Price-to-book ratio: market value relative to book equity. 1.0
P/S ?Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable. –
EV/EBITDA ?Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero. –
Price/FCF ?Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up. –

Profitability

Gross Margin ?Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power. –
EBIT Margin ?EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes. -13.4%
Net Margin ?Net margin: what's left of sales as profit after ALL costs, interest, and taxes. –
Return on Equity ?Return on equity: how much profit does the company generate per year on shareholders' equity? -15.0%
Return on Assets ?Return on assets: how much profit the company generates from its total assets (equity and debt combined). –

Balance Sheet & Safety

Equity Ratio ?Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet. 58.6%
Debt/Equity ?Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity. 0.1
Altman Z″ ?Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks. –
Piotroski ?Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag. 4 out of 9

Growth

Sales Growth Last Quarter ?Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY). 45.60%
EPS Growth Last Quarter ?Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY). 7.50%
Sales Growth (Year) ?Sales growth in the last fiscal year versus the year before. 1.04%
Forward Sales Growth ?Sales growth analysts expect over the next 12 months — an estimate, not a guarantee. -64.72%
Forward EPS Growth ?Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee. -9.90%

Dividend

No dividend data is available for this stock yet.

Quality & Screener

Stage ?Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line. –
RS Rating ?Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks. –
EPS Rating ?Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth. –
Fundamental Rating ?Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below. D (44 out of 100)

Comparison

Industry comparison

The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.

Industry: Health Information Services

Industry comparison
Company Market cap ($B) P/E EV/EBITDA Gross Margin % EBIT Margin % Sales Growth (Year) % Perf. 1Y %
So-Young International Inc SY 0.2 – – – -13.4 1.0 -56.9
Veeva Systems Inc Class A VEEV 39.4 48.5 26.0 75.0 30.9 16.3 -9.5
BrightSpring Health Services, Inc. BTSG 11.9 77.4 22.3 12.4 3.4 14.6 169.0
Tempus AI, Inc. TEM 9.6 – 0.0 64.0 -24.3 83.4 -22.0
HealthEquity Inc HQY 8.8 39.6 18.0 70.7 29.3 9.5 18.3
10X Genomics Inc TXG 7.6 – 147.9 69.7 -11.3 5.3 328.5
Hinge Health, Inc. HNGE 7.1 10.9 – – 19.0 50.6 50.6
Doximity Inc DOCS 4.8 – 13.4 89.1 21.6 13.1 -58.5
Waystar Holding Corp. WAY 4.5 – 12.3 69.1 25.6 16.5 -29.0
Median of companies shown 7.6 44.0 18.0 69.7 19.0 14.6 -9.5

Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →

Quarters

Quarterly Figures

Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter (CNY m)
2024: Q2 · 407.4 CNY m Q2 2024: Q3 · 371.8 CNY m Q3 2024: Q4 · 369.2 CNY m Q4 2025: Q1 · 297.3 CNY m Q1 2025: Q2 · 378.7 CNY m Q2 2025: Q3 · 386.7 CNY m Q3 2025: Q4 · 454.4 CNY m Q4 2026: Q1 · 430.2 CNY m Q1

Source: fundamental data

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales (CNY m) Sales YoY (%) Net Margin (%) OCF (CNY m) FCF (CNY m)
2024: Q2 0.36 200.00 407 -1.10 4.60 – –
2024: Q3 0.36 227.30 372 -3.50 5.50 – –
2024: Q4 -7.70 -2,300.00 369 -5.50 -164.60 – –
2025: Q1 -0.52 -1,400.00 297 -6.60 -11.10 – –
2025: Q2 -0.30 -183.30 379 -7.00 -9.50 – –
2025: Q3 -1.03 -386.10 387 4.00 -16.60 – –
2025: Q4 -1.20 84.40 454 23.10 -23.60 – –
2026: Q1 -0.46 11.50 430 44.70 -11.40 -105 -302

What Do These Terms Mean?

EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Compare with other stocks →

Screening

Appears in These Scanners

This stock currently matches 1 of our scanner strategies — each hit links to the scanner.

Risk & Weakness

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Outlook

Analysts & Price Target

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Consensus Sell 1 = Strong buy … 5 = Strong sell
Analyst Ratings –
Price Target (average) –
Distance to price –

No price target is available for this stock.

AI classification

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.

How the Rating Is Built

The company

About the Company

So-Young International Inc. betreibt eine Online-Plattform für Gesundheitsdienstleistungen im Konsumbereich in der Volksrepublik China. Das Unternehmen bietet die So-Young-Mobile-App an, die Nutzern Zugang zu Wissen über medizinische Ästhetik, Community-Unterstützung und Terminbuchungen für Behandlungen bei medizinischem Fachpersonal und in ästhetisch-medizinischen Einrichtungen bietet; das Weixin-Mini-Programm zur Erkundung von Behandlungsoptionen, Preisvergleichen, Terminplanung, Teilnahme an Online-Beratungen und Nachverfolgung von Behandlungen; sowie Inhalte zur ästhetischen Medizin-Community über die Website soyoung.com. Die ästhetischen Zentren des Unternehmens bieten nicht-invasive bis minimalinvasive Behandlungen an, darunter gerätebasierte Optionen wie Thread Lifts, intensiv gepulstes Licht, Ultraschall-Facelifts, Picosekundenlaser und Körperkonturbehandlungen sowie injizierbare Behandlungen wie Skin Booster, Produkte auf Hyaluronsäurebasis, Botox sowie Kollagen der Typen I und III. Darüber hinaus ist das Unternehmen in Forschung und Entwicklung, Herstellung, Verkauf und Vertrieb von Lichttherapiegeräten tätig, darunter Excimer-Lasersysteme, UV-Excimer-Therapiegeräte, LED- und Rotlichttherapiesysteme sowie fortgeschrittene Laser- und Intense-Pulsed-Light-Technologien; chirurgische Lasergeräte, darunter Kohlendioxid-Laserapparate, Mehrwellenlängen- und Halbleiter-Lasersysteme für urologische Behandlungen sowie hydrodynamisch unterstützte Liposuktionssysteme für die plastische Chirurgie, sowie pneumatische Flüssigsprühgeräte zur Hautreinigung. Ferner bietet es injizierbare Produkte an sowie Vertriebs-, technische, Wartungs-, Installations-, Betriebsschulungs-, Fehlermelde- und Verpackungsdienstleistungen für Geräte; Gesundheitsdienstleistungen im Konsumbereich, darunter Dermatologie, Zahnheilkunde und Kieferorthopädie, körperliche Untersuchungen, Gynäkologie und Wochenbettbetreuung; Terminbuchungsdienste; sowie Content-Management durch Beauty-Tagebücher, Kurzvideos, Behandlungsbewertungen, redaktionelle Artikel und Chat-Nachrichten. Das Unternehmen wurde 2013 gegründet und hat seinen Hauptsitz in Peking, China.

IPO Year
2019
ISIN
US83356Q1085

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?